Summit Therapeutics Inc. (Nasdaq: SMMT) shares rose 4.96% to $18.42 on September 14 after new Phase 3 data showed partner Akeso’s ivonescimab significantly extended overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer in China. Median overall survival reached 30.8 months with ivonescimab compared with 22.6 months for pembrolizumab, an 8.2-month difference and a hazard ratio of 0.73.
The protocol-specified interim analysis included 398 patients after a median 36 months of follow-up. The 27% reduction in the measured risk of death was statistically significant, with a p-value of 0.009, adding overall survival confirmation to a trial that had already shown a major progression-free survival advantage.
The result is particularly important because pembrolizumab has become one of the defining standards of care in PD-L1-positive metastatic lung cancer. Demonstrating superiority to an established PD-1 inhibitor is a considerably stronger clinical proposition than beating placebo or an older chemotherapy regimen.
Yet the SMMT investment thesis still contains a major geographic caveat. HARMONi-2 was conducted entirely in China, sponsored and analyzed by Akeso. Ivonescimab is approved in China but remains investigational in Summit Therapeutics’ territories, including the United States and Europe.
Summit’s global HARMONi-7 trial therefore remains the study capable of determining whether the advantage can be reproduced across a multinational population and support a broader first-line lung cancer opportunity.
How convincing is the 30.8-month versus 22.6-month survival difference?
Overall survival is among the hardest oncology endpoints to dismiss because it measures whether patients live longer rather than relying on radiographic tumor assessments alone. In HARMONi-2, ivonescimab produced median overall survival of 30.8 months compared with 22.6 months for pembrolizumab.
The hazard ratio of 0.73 means the risk of death during the analysis period was 27% lower in the ivonescimab group. The 95% confidence interval ranged from 0.57 to 0.95, and the p-value of 0.009 met statistical significance.
The result is strengthened by the earlier progression-free survival analysis. HARMONi-2’s primary endpoint had already shown a PFS hazard ratio of 0.51, representing a 49% reduction in the measured risk of disease progression or death compared with pembrolizumab.
Having both PFS and OS favor the same therapy reduces concern that improved radiographic disease control merely delayed progression without extending life.
The trial was also randomized and double blind, reducing several forms of bias that can complicate interpretation of uncontrolled oncology studies.
Still, one study in one country does not automatically establish the same benefit globally. Population characteristics, subsequent therapies, diagnostic practices and treatment pathways can differ across countries, which is why Summit is running its own multinational confirmatory program.
Why is the PD-L1-high subgroup particularly interesting for Summit Therapeutics?
The overall HARMONi-2 population included tumors with PD-L1 expression of at least 1%, but the strongest survival signal appeared among patients with high expression of at least 50%.
In that subgroup of 168 patients, the descriptive overall-survival hazard ratio was 0.58, corresponding to a 42% reduction in the measured risk of death relative to pembrolizumab. The confidence interval ranged from 0.38 to 0.89.
The lower-expression subgroup produced a more modest hazard ratio of 0.85, with a confidence interval crossing 1.0. These subgroup analyses were not formally powered to prove separate superiority and should not be treated as independent pivotal findings.
They are nevertheless strategically important because Summit designed global HARMONi-7 specifically for first-line metastatic NSCLC with PD-L1 expression above 50%.
That trial is expected to enroll approximately 780 patients and directly compare ivonescimab with pembrolizumab, with progression-free survival and overall survival as co-primary endpoints.
In other words, HARMONi-7 is testing the population in which the China data currently look most differentiated. If the PD-L1-high survival effect reproduces globally, the commercial implications could be substantial because pembrolizumab monotherapy is deeply established in this setting.
How does ivonescimab differ biologically from pembrolizumab?
Pembrolizumab inhibits PD-1, releasing an immune checkpoint that tumors can exploit to suppress T-cell activity. Ivonescimab incorporates PD-1 blockade but adds simultaneous inhibition of vascular endothelial growth factor, or VEGF, within the same tetravalent bispecific antibody.
VEGF is best known for promoting angiogenesis, allowing tumors to build blood vessels supporting growth. The pathway also influences the immune microenvironment, meaning VEGF blockade can potentially improve immune-cell access and reduce some mechanisms of immunosuppression.
Combining immunotherapy and anti-angiogenesis is not a completely new oncology concept. Separate PD-1 or PD-L1 inhibitors and VEGF-directed drugs have already been combined successfully in several cancers.
Ivonescimab’s proposed innovation is putting both activities into one engineered molecule. Akeso designed the antibody to bind cooperatively, with stronger PD-1 engagement in the presence of VEGF, theoretically concentrating activity within tumor environments where both targets are abundant.
That architecture may help produce stronger antitumor activity without simply reproducing the toxicity of administering two independent full-dose antibodies.
The concept is attractive, but the clinical dataset remains more important than structural elegance. HARMONi-2 provides evidence that the combined mechanism can outperform isolated PD-1 blockade in one population. HARMONi-7 must determine whether that remains true globally.
Does ivonescimab pay a safety price for adding VEGF blockade?
The new analysis presents a nuanced picture. Serious treatment-related adverse events occurred in 29.9% of patients receiving ivonescimab compared with 21.6% receiving pembrolizumab.
That higher rate deserves attention because combining an additional biological mechanism can increase toxicity even when efficacy improves.
At the same time, treatment-related adverse events causing discontinuation occurred in 4.1% of ivonescimab patients and 5.0% of pembrolizumab patients. Summit and Akeso also reported no new safety signal with longer follow-up.
Patients received a median 14 cycles of ivonescimab compared with 10 cycles of pembrolizumab, meaning the experimental group also accumulated longer treatment exposure.
VEGF inhibition can be associated with hypertension, proteinuria, bleeding, thrombosis and other vascular events, while PD-1 blockade can produce immune-related toxicities affecting several organs. A combination product therefore requires careful characterization of both risk categories.
The commercial benefit-risk calculation will depend on the magnitude of survival improvement. A significant extension of life can justify somewhat greater toxicity in metastatic cancer, but clinicians will scrutinize whether the additional adverse-event burden remains manageable in routine populations less selected than clinical-trial participants.
Why can’t Summit simply use HARMONi-2 to claim superiority in the United States?
The trial provides highly relevant evidence, but U.S. regulatory strategy cannot be reduced to importing a China-only result. The FDA evaluates whether study populations, standards of care, trial conduct and other factors support application to U.S. patients.
Summit has therefore built a parallel global clinical program. HARMONi-7 is the most direct counterpart to HARMONi-2 for the PD-L1-high first-line population, while other global trials are evaluating ivonescimab across additional NSCLC and gastrointestinal settings.
Ivonescimab already has a separate U.S. regulatory process underway. Summit submitted a Biologics License Application based on the global HARMONi trial in EGFR-mutant NSCLC after progression on an EGFR tyrosine kinase inhibitor, and the FDA has set a November 14, 2026 action date.
That application addresses a different treatment setting and combination regimen from HARMONi-2.
The coming months therefore contain two distinct investor narratives. One is whether FDA grants the first U.S. ivonescimab approval in the previously treated EGFR-mutant setting. The other is whether global HARMONi-7 can validate the much larger commercial ambition of challenging pembrolizumab directly in first-line PD-L1-high disease.
How large is Summit Therapeutics’ economic exposure to ivonescimab?
Ivonescimab was developed by Akeso, while Summit licensed rights across the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa.
Summit initially committed $500 million upfront for the partnership and later expanded the licensed territory. Akeso is also eligible for billions of dollars in additional regulatory and commercial milestones plus low double-digit royalties on net sales in Summit’s territories.
That means ivonescimab does not carry the economics of a fully internally discovered asset. Summit must share substantial future value with Akeso.
The trade-off is that Summit gained access to a molecule already supported by an extensive Chinese clinical-development program rather than funding discovery from its earliest stages.
The company has since invested heavily in global trials and has repeatedly raised capital to expand development. A $500 million public offering initiated in June 2026 illustrates the scale of the financial commitment required to test ivonescimab across multiple Phase 3 indications.
For SMMT investors, the breadth of the program is both strength and risk. Success in multiple cancers could support a major oncology franchise, while large global studies consume substantial cash before commercial revenue is assured.
Why does the September 14 stock move matter for SMMT sentiment?
SMMT closed at $18.42, up 4.96% on volume of nearly seven million shares. The gain extends a recovery that has taken the stock well above its late-August levels, though it remains below the 52-week high above $29.
The market reaction suggests investors view overall-survival confirmation as meaningful but are not treating HARMONi-2 as equivalent to a completed global registration study.
That restraint is reasonable. The China dataset has become increasingly impressive, but Summit’s valuation already reflects substantial expectations around ivonescimab.
The November FDA decision provides a nearer-term binary catalyst, while HARMONi-7 represents a potentially larger but longer-duration value driver.
SMMT also has a strong following among retail biotechnology investors because essentially the entire company thesis revolves around whether one bispecific antibody can disrupt several established cancer treatment markets. Every comparative dataset therefore has unusually direct implications for enterprise value.
What should SMMT investors watch next?
The November 14 FDA action date is the most immediate regulatory catalyst. Approval would give Summit its first commercial product in the United States and provide important validation of its ability to execute beyond Akeso’s China franchise.
HARMONi-7 remains the pivotal scientific catalyst for the pembrolizumab-comparison story. Enrollment progress and eventual PFS and OS results will determine whether the striking HARMONi-2 advantage can cross geographic boundaries.
Safety will remain under scrutiny as more patients receive the drug globally, especially if ivonescimab expands into earlier-line settings where treatment durations can be lengthy.
Investors should also watch how the PD-L1-high subgroup performs in future studies because that is where the HARMONi-2 survival advantage looks strongest and where Summit has concentrated HARMONi-7.
Ivonescimab has moved beyond a speculative bispecific concept. It has now beaten pembrolizumab on progression-free survival and overall survival in a randomized Phase 3 study in China.
The remaining question is the one that can ultimately determine whether SMMT becomes a major oncology company: can that advantage survive a large global head-to-head trial against one of the world’s most successful cancer medicines?
